Preston Klassen

2012 - Orexigen Therapeutics

In 2012, Preston Klassen earned a total compensation of $1.3M as Head of Global Contrave Program and Executive Vice President, Product Development at Orexigen Therapeutics, a 41% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$240,500
Option Awards$655,795
Salary$370,000
Other$120
Total$1,266,415

Klassen received $655.8K in option awards, accounting for 52% of the total pay in 2012.

Klassen also received $240.5K in non-equity incentive plan, $370K in salary and $120 in other compensation.

Rankings

In 2012, Preston Klassen's compensation ranked 5,206th out of 11,487 executives tracked by ExecPay. In other words, Klassen earned more than 54.7% of executives.

ClassificationRankingPercentile
All
5,206
out of 11,487
55th
Division
Manufacturing
1,819
out of 4,253
57th
Major group
Chemicals And Allied Products
436
out of 1,198
64th
Industry group
Drugs
285
out of 920
69th
Industry
Pharmaceutical Preparations
224
out of 700
68th
Source: SEC filing on April 22, 2015.

Klassen's colleagues

We found four more compensation records of executives who worked with Preston Klassen at Orexigen Therapeutics in 2012.

2012

Michael Narachi

Orexigen Therapeutics

Chief Executive Officer

2012

Joseph Hagan

Orexigen Therapeutics

Chief Business and Financial Officer

2012

Heather Turner

Orexigen Therapeutics

General Counsel

2012

Mark Booth

Orexigen Therapeutics

Chief Commercial Officer outgoing

News

In-depth

You may also like